Pantoprazole
Proton Pump Inhibitors
Sold as Somac Control · TECTA · Pantozol Control · Pantoloc Control · Pantecta Control
- Drug class
- Proton Pump Inhibitors
- Availability
- Prescription only
- Routes
- Intravenous, Oral
- Markets covered
- 4
- Products on record
- 130
- FDA reports (12 mo)
- 18,839
Overview
Plain-language summary, compiled from the cited regulatory records
Pantoprazole is a medication belonging to the drug class of proton pump inhibitors [1]. It is approved for the treatment of gastroesophageal reflux disease (GERD) with a history of erosive esophagitis in adults, for up to 10 days [1]. Additionally, it is indicated for pathological hypersecretory conditions, such as Zollinger-Ellison Syndrome, in adults [1].
The safety and effectiveness of pantoprazole sodium for injection in treating upper gastrointestinal bleeding have not been established in adult or pediatric patients [1]. Pantoprazole is available under various brand names, including Protonix Delayed-Release [1].
In the past 12 months, there have been 18,839 adverse event reports associated with pantoprazole [2]. The most frequently reported events include off-label use, fatigue, nausea, diarrhea, and headache [2].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| CA Canada | Health Canada | 55 | May 22, 2026 |
| GB United Kingdom | MHRA | 47 | May 15, 2026 |
| US United States | FDA | 25 | May 18, 2026 |
| EU European Union | EMA | 3 | May 25, 2023 |
CACanada· Health Canada
55 products
Uses
1 Pediatrics The safety and effectiveness of pantoprazole sodium in children have not yet been established. Therefore, Health Canada has not authorized an indication for pediatric use. 2 Geriatrics No dosage adjustment is recommended based on age.
The daily dose used in elderly patients, as a rule, should not exceed the recommended dosage regimens.
How to take
GBUnited Kingdom· MHRA
47 products
Uses
• Pantoprazole is indicated for use in adults and adolescents 12 years of age and above for: Symptomatic gastro-oesophageal reflux disease. • Long-term management and prevention of relapse in reflux oesophagitis. 4).
How to take
USUnited States· FDA
25 products
Uses
1 Short-Term Treatment of Erosive Esophagitis Associated With Gastroesophageal Reflux Disease (GERD) PROTONIX is indicated in adults and pediatric patients five years of age and older for the short-term treatment (up to 8 weeks) in the healing and symptomatic relief of erosive esophagitis (EE).
For those adult patients who have not healed after 8 weeks of treatment, an additional 8-week course of PROTONIX may be considered. Safety of treatment beyond 8 weeks in pediatric patients has not been established. 2 Maintenance of Healing of Erosive Esophagitis PROTONIX is indicated for maintenance of healing of EE and reduction in relapse rates of daytime and nighttime heartburn symptoms in adult patients with GERD.
Controlled studies did not extend beyond 12 months. 3 Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome PROTONIX is indicated for the long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison (ZE) Syndrome.
EUEuropean Union· EMA
3 products
Uses
PANTOZOL
g. heartburn, acid regurgitation) in adults.
How to take
Drug interactions
Known interactions involving Pantoprazole. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 577. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]Health Canada (DPD) · 02441527 · revised May 22, 2026
- [2]MHRA (UK) · PL044160708 · revised May 15, 2026
- [3]FDA DailyMed · 08098cb2-c048-46… · revised May 18, 2026 [PDF]
- [4]European Medicines Agency · EMEA/H/C/001013 · revised May 25, 2023
- [5]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.